Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Helix Therapeutics LLC

This article was originally published in Start Up

Executive Summary

Helix Therapeutics LLC aims to modify disease-linked genes on certain stem cells by introducing oligonucleotides that bind to double-stranded DNA inside a cell. Ideally, the oligos will bind tightly into the groove between strands of DNA and form a triple-stranded helix, or triplex, that prevents the gene from being read. If the results of Helix's animal experiments turn out to be replicable in humans, Helix may have a way of treating, and possibly even curing, sickle-cell disease and other disorders caused by genetic mutations.

Related Content

Start-Up Previews (03/2010)
Start-Up Previews (03/2010)


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts